NCT00191412已完成2 期
Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors
研究概览
简要总结
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of cancer of the liver which is metastatic or locally recurrent and not amendable to curative therapy.
- •Patient must have measurable disease
- •Patient may have received prior arterial chemoembolization, completed 8 weeks prior to study enrollment, but no other previous chemotherapy
- •Prior radiation is permitted, but must be completed at least 2 weeks prior to study enrollment.
- •Prior central nervous system metastases are acceptable if the patient has received radiation ot the brain, is not on steroids, and does not have related symptoms.
排除标准
- •Patients who have had prior therapy with Pemetrexed.
- •Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
- •Patients who have received radiation to more than 25% of marrow
结局指标
主要结局
Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors
次要结局
- Toxicity measured by CTCAE grading
- Duration of response: First complete or partial response until progressive disease (PD) or death of any cause
- Duration of stable disease: Enrollment to PD or death of any cause
- Time to treatment failure: Enroll. to PD, death of any cause, early discontinuation of treatment for any reason other than adequate response or start of new therapy
- Progression-free survival: Enroll. to PD or death of any cause
- Overall survival: Enroll. to death of any cause
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal CancerColorectal CancerNCT01126112Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)33
招募中
2 期
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaEGF-R Positive Non-Small Cell Lung CancerNSCLCNCT05165355Tongji University90
已完成
2 期
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.InfluenzaNCT05060887Osivax239
已完成
2 期
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerTriple Negative Breast CancerBreast CancerNCT05112536G1 Therapeutics, Inc.24
Unknown
2 期
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG RegimenMetastatic Pancreatic CancerNCT04101929Fudan University126